References
- Babb, J., A. Rogatko, and S. Zacks. 1998. Cancer phase I clinical trials: Efficient dose escalation with overdose control. Statistics in Medicine 17:1103–20. doi:https://doi.org/10.1002/(SICI)1097-0258(19980530)17:10<1103::AID-SIM793>3.0.CO;2-9.
- Chen, Z., A. Tighiouart, and J. Kowalski. 2012. Dose escalation with overdose control using a quasi-continuous toxicity score in cancer phase I clinical trials. Contemporary Clinical Trials 33:949–58. doi:https://doi.org/10.1016/j.cct.2012.04.007.
- Cheung, Y. K. 2011. Dose finding by the continual reassessment method. Boca Raton, FL: Chapman & Hall/CRC.
- Cheung, Y. K. 2014. Simple benchmark for complex dose finding studies. Biometrics 70:389–97. doi:https://doi.org/10.1111/biom.12158.
- Durham, S. D., N. Flournoy, and W. F. Rosenberger. 1997. A random walk rule for phase I clinical trials. Biometrics 53:745–60.
- Garrett-Mayer, E. 2006. The continual reassessment method for dose-finding studies: A tutorial. Clinical Trials 3:57–71. doi:https://doi.org/10.1191/1740774506cn134oa.
- Gezmu, M. and N. Flournoy. 2006. Group up-and-down designs for dose-finding. Journal of Statistical Planning and Inference 136:1749–64. doi:https://doi.org/10.1016/j.jspi.2005.08.002.
- Iasonos, A., A. S. Wilton, E. R. Riedel, V. E. Seshan, and D. R. Spriggs. 2008. A comprehensive comparison of the continual reassessment method to the standard 3 + 3 dose escalation scheme in Phase I dose-finding studies. Clinical Trials 5:465–77. doi:https://doi.org/10.1177/1740774508096474.
- Ivanova, A., N. Flournoy, and Y. Chung. 2007. Cumulative cohort design for dose finding. Journal of Statistical Planning and Inference 137:2316–27. doi:https://doi.org/10.1016/j.jspi.2006.07.009.
- Lee, S. M. and Y. K. Cheung. 2009. Model calibration in the continual reassessment method. Clinical Trials 6:227–38.
- Leung, D. and Y. Wang. 2002. An extension of the continual reassessment method using decision theory. Statistics in Medicine 21:51–63. doi:https://doi.org/10.1002/sim.970.
- Neuenschwander, B., M. Branson, and T. Gsponer. 2008 Critical aspects of the Bayesian approach to phase I cancer trials. Statistics in Medicine 27:2420–39. doi:https://doi.org/10.1002/sim.3230.
- O’Quigley, J. 1992. Estimating the probability of toxicity at the recommended dose following a Phase I clinical trial in cancer. Biometrics 48:853–63.
- O’Quigley, J. 2002. Continual reassessment designs with early termination. Biostatistics 3:87–99.
- O’Quigley, J., M. Pepe, and L. Fisher. 1990. Continual reassessment method: A practical design for Phase 1 clinical trials in cancer. Biometrics 46:33–48. doi:https://doi.org/10.2307/2531628.
- O’Quigley, J. and E. Reiner. 1998. A stopping rule for the continual reassessment method. Biometrika 85:741–8.
- O’Quigley, J. and L. Shen. 1996. Continual reassessment method: a likelihood approach. Biometrics 52:673–84. doi:https://doi.org/10.2307/2532905.
- Pan, H. and Y. Yuan. 2017. A default method to specify skeletons for Bayesian model averaging continual reassessment method for phase I clinical trials. Statistics in Medicine 36:266–79. doi:https://doi.org/10.1002/sim.6941.
- Potter, D. M. 2006. Phase I studies of chemotherapeutic agents in cancer patients: A review of the designs. Journal of Biopharmaceutical Statistics 16:579–604. doi:https://doi.org/10.1080/10543400600860295.
- Ratain, M. J., R. Mick, R. L. Schilsky, and M. Siegler. 1993. Statistical and ethical issues in the design and conduct of phase I and II clinical trials of new anticancer agents. Journal of the National Cancer Institute 85:1637–43. doi:https://doi.org/10.1093/jnci/85.20.1637.
- Rosenberger, W. and L. Haines. 2002. Competing designs for phase I clinical trials: a review. Statistics in Medicine 21:2757–70. doi:https://doi.org/10.1002/sim.1229.
- Shen, L. and J. O’Quigley. 1996. Consistency of continual reassessment method under model misspecification. Biometrika 83:395–405. doi:https://doi.org/10.1093/biomet/83.2.395.
- Simon, R., B. Freidlin, L. Rubinstein, G. Arbuck, J. Collins, and M. C. Christian. 1997. Accelerated titration designs for phase I clinical trials in oncology. Journal of the National Cancer Institute 89:1138–47. doi:https://doi.org/10.1093/jnci/89.15.1138.
- Storer, B. E. 1989. Design and analysis of phase I clinical trials. Biometrics 45:925–37. doi:https://doi.org/10.2307/2531693.
- Sverdlov, O., W. K. Wong, and Y. Ryeznik. 2014. Adaptive clinical trial designs for phase I cancer studies. Statistics Surveys 8:2–44. doi:https://doi.org/10.1214/14-SS106.
- Tighiouart, M. and A. Rogatko. 2010. Dose finding with escalation with overdose control (EWOC) in cancer clinical trials. Statistical Science 25:217–26. doi:https://doi.org/10.1214/10-STS333.
- Tighiouart, M., A. Rogatko, and J. S. Babb. 2005. Flexible Bayesian methods for cancer phase I clinical trials. Dose escalation with overdose control. Statistics in Medicine 24:2183–96. doi:https://doi.org/10.1002/sim.2106.
- Weber, J. S., L. A. Levit, P. C. Adamson, S. Bruinooge, H. A. Burris, M. A. Carducci, A. P. Dicker, M. Gönen, S. M. Keefe, M. A. Postow, M. A. Thompson, D. M. Waterhouse, S. L. Weiner, and L. M. Schuchter. 2015. American Society of Clinical Oncology policy statement update: The critical role of Phase I trials in cancer research and treatment. Journal of Clinical Oncology 33:278–84. doi:https://doi.org/10.1200/JCO.2014.58.2635.
- Wheeler, G. M., M. J. Sweeting, and A. P. Mander. 2017. Toxicity-dependent feasibility bounds for the escalation with overdose control approach in phase I cancer trials. Statistics in Medicine 36:2499–513. doi:https://doi.org/10.1002/sim.7280.
- Yin, G. and Y. Yuan. 2009. Bayesian model averaging continual reassessment method in Phase I clinical trials. Journal of the American Statistical Association 104:954–68. doi:https://doi.org/10.1198/jasa.2009.ap08425.
- Zacks, S., A. Rogatko, and J. Babb. 1998. Optimal Bayesian-feasible dose escalation for cancer phase I trials. Statistics and Probability Letters 38:215–20. doi:https://doi.org/10.1016/S0167-7152(98)00016-9.
- Zhou, H., Y. Yuan, and L. Nie. 2018. Accuracy, safety, and reliability of novel phase I trial designs. Clinical Cancer Research 24:4357–64. doi:https://doi.org/10.1158/1078-0432.CCR-18-0168.